Podocyte-Targeted Therapy in Focal Segmental Glomerulosclerosis: Insights from a Phase 2 Trial of TRPC6 Inhibition - PubMed
5 hours ago
- #Podocyte
- #Clinical Trial
- #FSGS
- Article discusses podocyte-targeted therapy in focal segmental glomerulosclerosis (FSGS) with insights from a Phase 2 trial involving TRPC6 inhibition.
- Trial results provide data on the potential efficacy and safety of TRPC6 inhibition as a therapeutic strategy for FSGS.
- Reference details include PMID 42144227 and DOI 10.1053/j.ajkd.2026.04.006, indicating a peer-reviewed journal publication.
- Publication types, full text sources, and additional resources are available for further exploration of the topic.